Clamp, A.R., Blackhall, F., Vasey, P., Soukop, M., Coleman, R., Halbert, G., Robson, L. and Jayson, G.C. (2003) A phase II trial of bryostatin-I administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma. British Journal of Cancer, 89, pp. 1152-1154. (doi: 10.1038/sj.bjc.6601285)
Full text not currently available from Enlighten.
Abstract
Bryostatin-1 is a macrocyclic lactone whose main mechanism of action is protein kinase C modulation. We investigated its activity as a weekly 24-h infusion in recurrent ovarian carcinoma. In all, 17 patients were recruited and 11 had chemotherapy-resistant disease as defined by disease progression within 4 months of last cytotoxic therapy. All were evaluable for toxicity and 14 for response. There were no disease responses and the main toxicity was myalgia.
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | UNSPECIFIED |
Authors: | Clamp, A.R., Blackhall, F., Vasey, P., Soukop, M., Coleman, R., Halbert, G., Robson, L., and Jayson, G.C. |
College/School: | College of Medical Veterinary and Life Sciences |
Journal Name: | British Journal of Cancer |
University Staff: Request a correction | Enlighten Editors: Update this record